Review





Similar Products

94
MedChemExpress pladienolide b
Pladienolide B, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pladienolide+b/Pladienolide+B/pm42994428-1111-248-250
Average 94 stars, based on 1 article reviews
pladienolide b - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology pladienolide b
Pladienolide B, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pladienolide+b/Pladienolide+B/pm42870295-51-4-6
Average 93 stars, based on 1 article reviews
pladienolide b - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

nab  (Tocris)
93
Tocris nab
Nab, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pladienolide+b/Pladienolide+B/pmc13752276-491-14-15
Average 93 stars, based on 1 article reviews
nab - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Eisai Inc natural product pladienolide b
Natural Product Pladienolide B, supplied by Eisai Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pladienolide+b/b+natural+pladienolide+product/pmc13031079-378-3-0
Average 86 stars, based on 1 article reviews
natural product pladienolide b - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology dmso
(a, b, c, d, e, f, h, i, j) Cropped immunoblots of SNRPB - and SNRPN -cells under various conditions. RNA Pol2, PCNA, GAPDH and Coomassie serve as loading controls. HA-antibody shows overall protein stability differences. Monoclonal SmB/B’/N antibody (clone 12F5) shows detection differences for SNRPN under certain conditions. All experiments were performed at least twice with similar results. For control conditions, the solvent <t>(DMSO,</t> Ethanol, Water) in which the inhibitors are dissolved were added to the media. (a) Truncation mutant of SNRPB - amino acids 1-190 versus 1-231 (full-length) (b) SNRPB/N mutants encoding only amino acids 190 until C-terminal end. (c) SNRPB/N -cells treated 27 hours with 5 μM of PRMT4/CARM1 (left) or 6 days with 10 μM of PRMT5 inhibitor (right). (d) SNRPB/N -cells treated with translation inhibitors Cycloheximide (CHX, 4 hours, 100 μg/mL) or Puromycin (PURO, 20 μM) (e) SNRPB/N -cells treated with mTOR inhibitor INK128 (320 μM). The pAKT blot serves as a positive control for effective treatment. (f) SNRPB/N -cells treated with splicing <t>inhibitor</t> <t>Pladienolide</t> B (PlaB, 16 hours, 100 nM). Effective treatment was evaluated by RT-qPCR, see Extended Data Fig. 5c. (g) Quantification of post-translational modifications (PTMs) by mass spectrometry, as in , including CHX-treated conditions. The experiment was performed together, so the same datapoints from are also shown here (control condition). Each replicate IP sample was split and digested with either elastase (circles) or trypsin (triangles) to generate peptides for mass spectrometry. (h) SNRPB/N -cells treated with NMD inhibitor hSMGi-11e (24 hours, 0.6 μM). Effective treatment was evaluated by RT-qPCR, see Extended Data Fig. 5i. (i) SNRPB/N -cells grown in regular media (1x), media containing no arginine (left, 0x) or no Lysine (right, 0x) or 10-fold higher arginine (left, 10x) or Lysine (right, 10x) concentrations. Treatment was conducted for 16 hours. (j) SNRPB/N -cells grown in regular media (lane 1), media containing L-Glutamine instead of L-Alanyl-L-Glutamine (lane 2), regular media (lane 3) or regular media with reduced glucose content (lane 4). Treatment was conducted for 16 hours.
Dmso, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pladienolide+b/Pladienolide+B/bio_rxiv__64898__2026__02__11__705284-251-12-7
Average 93 stars, based on 1 article reviews
dmso - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


(a, b, c, d, e, f, h, i, j) Cropped immunoblots of SNRPB - and SNRPN -cells under various conditions. RNA Pol2, PCNA, GAPDH and Coomassie serve as loading controls. HA-antibody shows overall protein stability differences. Monoclonal SmB/B’/N antibody (clone 12F5) shows detection differences for SNRPN under certain conditions. All experiments were performed at least twice with similar results. For control conditions, the solvent (DMSO, Ethanol, Water) in which the inhibitors are dissolved were added to the media. (a) Truncation mutant of SNRPB - amino acids 1-190 versus 1-231 (full-length) (b) SNRPB/N mutants encoding only amino acids 190 until C-terminal end. (c) SNRPB/N -cells treated 27 hours with 5 μM of PRMT4/CARM1 (left) or 6 days with 10 μM of PRMT5 inhibitor (right). (d) SNRPB/N -cells treated with translation inhibitors Cycloheximide (CHX, 4 hours, 100 μg/mL) or Puromycin (PURO, 20 μM) (e) SNRPB/N -cells treated with mTOR inhibitor INK128 (320 μM). The pAKT blot serves as a positive control for effective treatment. (f) SNRPB/N -cells treated with splicing inhibitor Pladienolide B (PlaB, 16 hours, 100 nM). Effective treatment was evaluated by RT-qPCR, see Extended Data Fig. 5c. (g) Quantification of post-translational modifications (PTMs) by mass spectrometry, as in , including CHX-treated conditions. The experiment was performed together, so the same datapoints from are also shown here (control condition). Each replicate IP sample was split and digested with either elastase (circles) or trypsin (triangles) to generate peptides for mass spectrometry. (h) SNRPB/N -cells treated with NMD inhibitor hSMGi-11e (24 hours, 0.6 μM). Effective treatment was evaluated by RT-qPCR, see Extended Data Fig. 5i. (i) SNRPB/N -cells grown in regular media (1x), media containing no arginine (left, 0x) or no Lysine (right, 0x) or 10-fold higher arginine (left, 10x) or Lysine (right, 10x) concentrations. Treatment was conducted for 16 hours. (j) SNRPB/N -cells grown in regular media (lane 1), media containing L-Glutamine instead of L-Alanyl-L-Glutamine (lane 2), regular media (lane 3) or regular media with reduced glucose content (lane 4). Treatment was conducted for 16 hours.

Journal: bioRxiv

Article Title: The splicing paralogues SNRPB and SNRPN control differential metabolic states

doi: 10.64898/2026.02.11.705284

Figure Lengend Snippet: (a, b, c, d, e, f, h, i, j) Cropped immunoblots of SNRPB - and SNRPN -cells under various conditions. RNA Pol2, PCNA, GAPDH and Coomassie serve as loading controls. HA-antibody shows overall protein stability differences. Monoclonal SmB/B’/N antibody (clone 12F5) shows detection differences for SNRPN under certain conditions. All experiments were performed at least twice with similar results. For control conditions, the solvent (DMSO, Ethanol, Water) in which the inhibitors are dissolved were added to the media. (a) Truncation mutant of SNRPB - amino acids 1-190 versus 1-231 (full-length) (b) SNRPB/N mutants encoding only amino acids 190 until C-terminal end. (c) SNRPB/N -cells treated 27 hours with 5 μM of PRMT4/CARM1 (left) or 6 days with 10 μM of PRMT5 inhibitor (right). (d) SNRPB/N -cells treated with translation inhibitors Cycloheximide (CHX, 4 hours, 100 μg/mL) or Puromycin (PURO, 20 μM) (e) SNRPB/N -cells treated with mTOR inhibitor INK128 (320 μM). The pAKT blot serves as a positive control for effective treatment. (f) SNRPB/N -cells treated with splicing inhibitor Pladienolide B (PlaB, 16 hours, 100 nM). Effective treatment was evaluated by RT-qPCR, see Extended Data Fig. 5c. (g) Quantification of post-translational modifications (PTMs) by mass spectrometry, as in , including CHX-treated conditions. The experiment was performed together, so the same datapoints from are also shown here (control condition). Each replicate IP sample was split and digested with either elastase (circles) or trypsin (triangles) to generate peptides for mass spectrometry. (h) SNRPB/N -cells treated with NMD inhibitor hSMGi-11e (24 hours, 0.6 μM). Effective treatment was evaluated by RT-qPCR, see Extended Data Fig. 5i. (i) SNRPB/N -cells grown in regular media (1x), media containing no arginine (left, 0x) or no Lysine (right, 0x) or 10-fold higher arginine (left, 10x) or Lysine (right, 10x) concentrations. Treatment was conducted for 16 hours. (j) SNRPB/N -cells grown in regular media (lane 1), media containing L-Glutamine instead of L-Alanyl-L-Glutamine (lane 2), regular media (lane 3) or regular media with reduced glucose content (lane 4). Treatment was conducted for 16 hours.

Article Snippet: A 1 mM stock of Pladienolide B (Santa Cruz Biotechnology, sc-391691) in DMSO was diluted to 100 nM for 16-hours.

Techniques: Western Blot, Control, Solvent, Mutagenesis, Positive Control, Quantitative RT-PCR, Mass Spectrometry